Marine organisms with anti-diabetes properties

Marine Drugs

Volumn 14, Issue 12, 2016, Pages

  Lauritano, Chiara ^a   Ianora, Adrianna ^a  

^a STAZIONE ZOOLOGICA ANTON DOHRN   (Italy)

Author keywords

Diabetes; Drug discovery; Marine biotechnology; Marine organisms; Metabolic disorder; Microalgae

Indexed keywords

2,4 DIBROMOPHENOL; 2,4,6 TRIBROMOPHENOL; 3,4 DIBROMO 5 [2 BROMO 3,4 DIHYDROXY 6 (ETHOXYMETHYL)BENZYL]BENZENE 1,2 DIOL; AMYLASE; ASTAXANTHIN; BROMOPHENOL; CALLYSPONGYNIC ACID; CHLORELLA ZOFINGIENSIS EXTRACT; DIECKOL; DIPHLORETHOHYDROXYCARMALOL; DYSIDINE; ECKOL; FUCOXANTHIN; NATURAL PRODUCT; PALINURIN; PHENYLMETHYLENE HYDANTOIN; POLYBROMODIPHENYL ETHER; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT;

ACTINOBACTERIA; ANTIDIABETIC ACTIVITY; ANTIOXIDANT ACTIVITY; BROWN ALGA; CHLORELLA PYRENOIDOSA; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID METABOLISM; MARINE SPECIES; MICROALGA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SEAWEED; SPONGE (PORIFERA); STREPTOMYCES; ANIMAL; ANTHOZOA; AQUATIC SPECIES; BACTERIUM; CHEMISTRY; FISH;

ANIMALS; ANTHOZOA; ANTIHYPERTENSIVE AGENTS; AQUATIC ORGANISMS; BACTERIA; DIABETES MELLITUS; FISHES; HUMANS; HYPOGLYCEMIC AGENTS; MICROALGAE; PORIFERA; SEAWEED;

EID: 85007508307     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md14120220     Document Type: Review

References (86)

1. Kaur, J. A comprehensive review on metabolic syndrome. Cardiol. Res. Pract. 2014, 2014, 943162. [CrossRef] [PubMed]
2. Barde, S. R.; Sakhare, R. S.; Kanthale, S. B.; Chandak, P. C.; Jamkhande, P. C. Marine bioactive agents: A short review on new marine antidiabetic compounds. Asian Pac. I. Trop. Dis. 2015, 5, S209-S213. [CrossRef]
3. Mathers, CD.; Loncar, D. Proections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006, 3, e442. [CrossRef] [PubMed]
4. Liu, Y.; Gao, Z.; Guo, Q.; Wang, T.; Lu, C.; Chen, Y.; Sheng, Q.; Chen, J.; Nie, Z.; Zhang, Y.; et al. Anti-Diabetic Effects of CTB-APSL Fusion Protein in Type 2 Diabetic Mice. Mar. Drugs 2014, 12, 1512-1529. [CrossRef] [PubMed]
5. Joshi, S. R.; Parikh, R. M.; Das, A. K. Insulin-History, biochemistry, physiology and pharmacology. I. Assoc. Physicians India 2007, 55, 519-525.
6. Newsholme, P.; Cruzat, V.; Arfuso, F.; Keane, K. Nutrient regulation of insulin secretion and action. J. Endocrinol. 2014, 221, R105-R120. [CrossRef] [PubMed]
7. Sonksen, P.; Sonksen, J. Insulin: Understanding its action in health and disease. Br. J. Anaesth. 2000, 85, 69-79. [CrossRef] [PubMed]
8. D'Orazio, N.; Cammone, M. A.; Cemello, E.; Dc Cirolamo, M.; Cusenza, S.; Riccioni, C. Marine bioactives: Pharmacological properties and potential applications against inflammatory diseases. Mar. Drugs 2012, 10, 812-833. [CrossRef] [PubMed]
9. Rewers, M.; Ludvigsson, [. Environmental risk factors for type 1 diabetes. Lancet 2016, 387, 2340-2348. [CrossRef]
10. Reimann, M.; Bonifaci, E.; Solimena, M.; Schwarz, P. E.; Ludwig, B.; Hanefeld, M.; Bornstein, S. R. An update on preventive and regenerative therapies in diabetes mellitus. Phartnacol. Ther. 2009, 121, 317-331. [CrossRef] [PubMed]
11. Popov, A. M.; Krivoshapko, ON. Protective effects of polar lipids and redox-active compounds from marine organisms at modeling of hyperlipidemia and diabetes. I. Biotned. Sci. Eng. 2013, 6, 543-550. [CrossRef]
12. Zhang, Z.; Zhao, M.; Wang, J.; Ding, Y.; Dai, X.; Li, Y. Oral administration of skin gelatin isolated from chum salmon (Oncorhynchus keta) enhances wound healing in diabetic rats. Mar. Drugs 2011, 9, 696-711. [CrossRef] [PubMed]
13. Zhu, C. F.; Peng, RB.; Liu, G. Q.; Zhang, F.; Li, Y Beneficial effects of oligopeptides from marine salmon skin in a rat model of type 2 diabetes. Nutrition 2010, 26, 1014-1020. [CrossRef] [PubMed]
14. Costantino, V.; Fattorusso, E.; Imperatore, C.; Mangoni, A. Ectyoceramide, the First Natural Hexofuranosylceramide from the Marine Sponge Ectyoplasia ferox. Eur. I. Org. Client. 2003, 1433-143 7. [CrossRef]
15. Costantino, V.; Fattorusso, E.; Imperatore, C.; Mangoni, A. Glycolipids from sponges. 20. J-coupling analysis for stereochemical assignments in furanosides: Structure elucidation of vesparioside B, a glycosphingolipid from the marine sponge Spheciospongia vesparia. I. Org. Client. 2008, 73, 6158-6165. [PubMed]
16. Jaspars, M.; Del'ascale, U.; Andersen, J. H.; Reyes, F.; Crawford, AD.; lanora, A. The marine biodiscovery pipeline and ocean medicines of tomorrow. I. Mar. Biol. Assoc. U. K. 2016, 96, 151-158. [CrossRef]
17. Romano, C.; Costantini, M.; Sansone, C.; Lauritano, C.; Ruocco, N.; Janora, A. Marine microorganisms as a promising and sustainable source of bioactive molecules. Mar. Environ. Res. 2016. [CrossRef I [PubMedi
18. Lowenberg, B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 2013, 121, 26-28. [CrossRef] [PubMed]
19. Schoffski, F; Dumez, H.; Wolter, F; Stefan, C.; Wozniak, A.; Jimeno, J.; Van Oosterom, AT. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin. Pharniacother. 2008, 9, 1609-1618. [CrossRef] [PubMed]
20. Menis, J.; Twelves, C. Eribulin (Halaven): A new, effective treatment for women with heavily pretreated metastatic breast cancer. Breast Cancer Targets Ther. 2011, 3, 101-111. [CrossRef] [PubMed]
21. Klotz, U. Ziconotide-A novel neuron-specific calcium charmel blocker for the intrathecal treatment of severe chronic pain-A short review. mt. j. Clin. Pharniacol. Ther. 2006, 44, 478-483. [CrossRef] [PubMed]
22. Sagar, S.; Kaur, M.; Minneman, K. P. Antiviral lead compounds from marine sponges. Mar. Drugs 2010, 8, 2619-2638. [CrossRef] [PubMed]
23. Malve, H. Exploring the ocean for new developments: Marine pharmacology. J. Phartn. Bioallied Sci. 2016, 8, 83-91. [CrossRef] [PubMed]
24. Bidon-Chanal, A.; Fuertes, A.; Alonso, D.; Perez, DI.; Martinez, A.; Luque, F. J.; Medina, M. Evidence for a new binding mode to GSK-3: Allosteric regulation by the marine compound palinurin. Eur. I. Med. Chenz. 2013, 60, 479-489. [CrossRef] [PubMed]
25. Harnedy, PA.; FitzGerald, R. J. In vitro assessment of the cardioprotective, anti-diabetic and antioxidant potential of Paltnaria paltnata protein hydrolysates. I. Appl. Phycol. 2013, 25, 1793-1803. [CrossRef]
26. Imada, C. Enzyme inhibitors and other bioactive compounds from marine actinomycetes. Antonie Van Leeuwenhoek 2005, 87, 59-63. [CrossRef] [PubMed]
27. Kim, KY.; Nam, K. A.; Kurihara, H.; Kim, S. M. Potent cx glucosidase inhibitors purified from the red algae Grateloupia elliptica. Phytochetnistry 2008, 69, 2820-2825. [CrossRef] [PubMed]
28. Krish, S.; Das, A. In-vitro bioactivity of marine seaweed, Cladophora rupestris. mt. j. Phartn. Biol. Sci. 2014, 5, 898-908.
29. Nwosu, E; Morris, J.; Lund, V. A.; Stewart, D.; Ross, H. A.; McDougall, G. J. Anti-proliferative and potential anti-diabetic effects of phenolic-rich extracts from edible marine algae. Food Chenz. 2011, 126, 1006-1012. [CrossRef]
30. Pandey, S.; Sree, A.; Dash, S. S.; Sethi, D. P.; Chowdhury, L. Diversity of marine bacteria producing beta-glucosidase inhibitors. Microb. Cell Fact. 2013, 12. [CrossRef] [PubMed]
31. Sun, Z.; Chen, F. Evaluation of the Green Alga Chlorella pyrenoidosa for management of diabetes. I. Food Drug Anal. 2012, 20, 246-249.
32. Lebovitz, H. E. Oral antidiabetic agents: The emergence of cxglucosidase inhibitors. Drugs 1992, 44, 21-28. [CrossRef] [PubMed]
33. Suzen, S.; Buyukbingol, E. Recent studies of aldose reductase enzyme inhibition for diabetic complications. Curr. Med. Chenz. 2003, 10, 1329-1352. [CrossRef] [PubMed]
34. Lankas, G. R.; Leiting, B.; Roy, R. S.; Eiermann, G. J.; Beconi, M. G.; Biftu, T.; Chan, C. C.; Edmondson, S.; Feeney, W. P.; He, H.; et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005, 54, 2988-2994. [CrossRef] [PubMed]
35. Henriksen, E. J.; Dokken, B. B. Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr. Drug Targets 2006, 7, 1435-1441. [CrossRef] [PubMed]
36. Sharifuddin, Y.; Chin, Y. X.; Lim, FE.; Phang, SM. Potential bioactive compounds from seaweed for diabetes management. Mar. Drugs 2015, 13, 5447-5491. [CrossRef] [PubMed]
37. Shi, D.; Guo, S.; hang, B.; Guo, C.; Wang, T.; Zhang, L.; Li, J. HPN, a synthetic analogue of bromophenol from red alga Rhodotnela confervoides: Synthesis and anti-diabetic effects in C57BL/Ks]-db/db mice. Mar. Drugs 2013, 11, 350-362. [CrossRef] [PubMed]
38. Yamazaki, H.; Nakazawa, I.; Sumilat, D. A.; Takahashi, 0.; Ukai, K.; Takahashi, S.; Namikoshi, M. Euryspongins A-C, three new unique sesquiterpenes from a marine sponge Euryspongia sp. Bioorg. Med. Chenz. Lett. 2013, 23, 2151-2154. [CrossRef] [PubMed]
39. Kang, C.; Jin, YB.; Lee, H.; Cha, M.; Sohn, li-I.; Moon, J.; Park, C.; Chun, S.; Jung, li-S.; Hong, J.-S.; et al. Brown alga Ecklonia cava attenuates type 1 diabetes by activating ampk and akt signaling pathways. Food Chenz. Toxicol. 2010, 48, 509-516. [CrossRef] [PubMed]
40. Nuno, K.; Villarruel-López, A.; Puebla-Pérez, A. M.; Romero-Velarde, E.; Puebla-Mora, AG.; Ascencio, E Effects of the marine microalgae Isochrysis galbana and Nannochloropsis oculata in diabetic rats. I. Funct. Foods 2013, 106-115. [CrossRef]
41. Tamrakar, A. K.; Tiwari, P.; Ahmad, R.; Kumar, R.; Lakshmi, V.; Srivastava, M. N.; Srivastava, A. K. Antihyperglycaemic activity of Sinularia firma and Sinularia erecta in streptozotocin-induced diabetic rats. Med. Chem. Res. 2008, 17, 62-73. [CrossRef]
42. Tiwari, P.; Rahuja, N.; Kumar, R.; Lakshmi, V.; Srivastava, M. N.; Agarwal, S. C.; Raghubir, R.; Srivastava, A. K. Search for antthyperglycemic activity in few marine flora and fauna. Indian J. Sci. Technol. 2008, 1, 1-5.
43. Sun, Z.; Peng, X.; Liu, J.; Fan, K.-W.; Wang, M.; Chen, F. Inhibitory effects of microalgal extracts on the formation of advanced glycation endproducts (AGEs). Food Chem. 2010, 120, 261-267. [CrossRef]
44. Zorena, K.; Raczyñska, D.; Raczyñska, K. Biomarkers in diabetic retinopathy and the therapeutic implications. Mediat. Injlamm. 2013, 2013, 193604. [CrossRefj [PubMed]
45. Sun, Z.; Liu, J.; Zeng, X.; Huangfu, J.; hang, Y.; Wang, M.; Chen, F. Protective actions of microalgae against endogenous and exogenous advanced glycation endproducts (AGEs) in human retinal pigment epithelial cells. Food Funct. 2011, 2, 251-258. [CrossRef] [PubMed]
46. Cannell, R. J.; Kellam, S. J.; Owsianka, A. M.; Walker, [. M. Microalgae and cyanobacteria as a source of glycosidase inhibitors. J. Gen. Microbiol. 1987, 133, 1701-1705. [CrossRef] [PubMed]
47. Debbab, A.; Aly, A. H.; Lin, W. H.; Froksch, F. Bioactive compounds from marine bacteria and fungi. Microb. Biotechnol. 2010, 3, 544-563. [CrossRef] [PubMed]
48. lanora, A.; Miralto, A.; Poulet, S. A.; Carotenuto, Y.; Buttino, I.; Romano, C.; Casotti, R.; Pohnert, C.; Wichard, I.; Colucci-D'Amato, L.; et al. Aldehyde suppression of copepod recruitment in blooms of a ubiquitous planktonic diatom. Nature 2004, 429, 403-407. [CrossRef] [PubMed]
49. Carotenuto, Y.; Esposito, E; Pisano, E; Lauritano, C.; Perna, M.; Miralto, A.; lanora, A. Multigeneration cultivation of the cop epod Calanus helgolandicus in a re-circulating system. I. Exp. Mar. Biol. Ecol. 2012, 418, 46-58. [CrossRef]
50. Sun, Z.; Liu, J.; Zeng, X.; Huangfu, J.; hang, Y.; Wang, M.; Chen, E Astaxanthin is responsible for antiglycoxidative properties of microalga Chlorella zofingiensis. Food Chem. 2011, 126, 1629-1635. [CrossRef] [PubMed]
51. Miki, W. Biological functions and activities of animal carotenoids. Pure Appl. Chem. 1991, 63, 141-146. [CrossRef]
52. Lauritano, C.; Andersen, J. H.; Hansen, E.; Albrigtsen, M.; Escalera, L.; Esposito, F.; Helland, K.; Hanssen, K.; Romano, G.; lanora, A. Bioactivity screening of microalgae for antioxidant, anti-inflammatory, anticancer, anti-diabetes and antibacterial activities. Front. Mar. Sci. 2016, 3. [CrossRef]
53. Ingebrigtsen, R. A.; Hansen, E.; Andersen, [H.; Eilertsen, H. C. Light and temperature effects on bioactivity in diatoms. I. Appl. Phycol. 2015, 28, 939-950. [CrossRef] [PubMed]
54. Liu, X.; Li, X.; Gao, L.; Cui, C.; Li, C.; Li, J.; Wang, B. Extraction and PTP1B inhibitory activity of bromophenols from the marine red alga Symphyocladia latiuscula. Chin. J. Oceanol. Limnol. 2011, 29, 686-690. [CrossRef]
55. Shi, D.; Li, J.; hang, B.; Guo, S.; Su, H.; Wang, I. Bromophenols as inhibitors of protein tyrosine phosphatase lB with antidiabetic properties. Bioorg. Med. Chem. Lett. 2012, 22, 2827-2832. [CrossRef] [PubMed]
56. Wang, W.; Okada, Y.; Shi, H.; Wang, Y.; Okuyama, T. Structures and aldose reductase inhibitory effects of bromophenols from the red alga Symphyocladia latiuscula. J. Nat. Prod. 2005, 68, 620-622. [CrossRef] [PubMed]
57. Lee, Y. S.; Shin, K. H.; Kim, B. K.; Lee, S. Anti-diabetic activities of fucosterol from Pelvetia siliquosa. Arch. Pharm. Res. 2004, 27, 1120-1122. [CrossRef] [PubMed]
58. Iwai, K. Antidiabetic and antioxidant effects of polyphenols in brown alga Ecklonia stolonifera in genetically diabetic KK-A(y) mice. Plant Foods Hum. Nutr. 2008, 63, 163-169. [CrossRef] [PubMed]
59. Jung, H. A.; Yoon, N. Y.; Woo, M. H.; Choi, J. S. Inhibitory activities of extracts from several kinds of seaweeds and phlorotannins from the brown alga Ecklonia stolonifera on glucose-mediated protein damage and rat lens aldose reductase. Fish. Sci. 2008, 74, 1363-1365. [CrossRef]
60. Thomas, NV.; Kim, S. K. Potential pharmacological applications of polyphenolic derivatives from marine brown algae. Environ. Toxicol. Pharmacol. 2011, 32, 325-335. [CrossRef] [PubMed]
61. Okada, Y.; Ishimaru, A.; Suzuki, R.; Okuyama, I. A new phloroglucinol derivative from the brown alga Eisenia bicyclis: Potential for the effective treatment of diabetic complications. J. Nat. Prod. 2004, 67, 103-105. [CrossRef I [PubMed]
62. Heo, S. J.; Hwang, J. Y.; Choi, J. I.; Han, J. S.; Kim, H. J.; Jeon, Y. J. Diphlorethohydroxycarmalol isolated from Ishige okamurae, a brown algae, a potent alpha-glucosidase and alpha-amylase inhibitor, alleviates postprandial hyperglycemia in diabetic mice. Eur. J. Pharmacol. 2009, 615, 252-256. [CrossRefj [PubMed]
63. Celikler, S.; las, S.; Vatan, 0.; Ziyanok-Ayvalik, S.; Yildiz, C.; Bilaloglu, R. Anti-hyperglycemic and antigenotoxic potential of Ulva rigida ethanolic extract in the experimental diabetes mellitus. Food Chem. Toxicol. 2009, 47, 1837-1840. [CrossRef I [PubMed]
64. Cokce, C.; Haznedaroglu, M. Z. Evaluation of antidiabetic, antioxidant and vasoprotective effects of Posidonia oceanica extract. I. Ethnopharmacol. 2008, 115, 122-130. [CrossRef] [PubMed]
65. Lee, H. J.; Kim, Y. A.; Lee, J. I.; Lee, B. J.; Seo, Y. W. Screening of Korean marine plants extracts for inhibitory activity on protein tyrosine phosphatase lB. I. Appl. Biol. Chem. 2007, 50, 74-77.
66. Kimura, Y.; Watanabe, K.; Okuda, H. Effects of soluble sodium alginate on cholesterol excretion and glucose tolerance in rats. I. Ethnopharmacol. 1996, 54, 47-54. [CrossRef]
67. Esposito, C.; Teta, R.; Miceli, R.; Ceccarelli, L. S.; Della Sala, C.; Camerlingo, R.; Irollo, E.; Mangoni, A.; Pirozzi, C.; Costantino, V. Isolation and assessment of the in vitro anti-tumor activity of smenothiazole A and B, chlorinated thiazole-containing peptide/polyketides from the Caribbean sponge, Smenospongia aurea. Mar. Drugs 2015, 13, 444-459. [CrossRef] [FubMed]
68. Mehbub, ME; Lei, J.; Franco, C.; Zhang, W. Marine Sponge Derived Natural Products between 2001 and 2010: Trends and Opportunities for Discovery of Bioactives. Mar. Drugs 2014, 12, 4539-4577. [CrossRef] [PubMed]
69. Lamoral-Theys, D.; Fattorusso, E.; Mangoni, A.; Perinu, C.; Kiss, R.; Costantino, V. Evaluation of the antiproliferative activity of diterpene isonitriles from the sponge Pseudoaxinellajlava in apoptosis-sensitive and apoptosis-resistant cancer cell lines. J. Nat. Prod. 2011, 74, 2299-2303. [CrossRef] [PubMed]
70. Costantino, V.; Fattorusso, E.; Imperatore, C.; Mangoni, A.; Freigang, S.; Teyton, L. Corrugoside, a new immunostimulatory alpha-galactoglycosphingolipid from the marine sponge Axinella corrugata. Bioorg. Med. Chem. 2008, 16, 2077-2085. [CrossRef] [PubMed]
71. Khanfar, M. A.; Asal, B. A.; Mudit, M.; Kaddoumi, A.; El Sayed, K. A. The marine natural-derived inhibitors of glycogen synthase kinase-313 phenylmethylene hydantoins: In vitro and in vivo activities and pharmacophore modeling. Bioorg. Med. Chem. 2009, 17, 6032-6039. [CrossRef I [PubMed]
72. Nakao, Y.; Uehara, I.; Matunaga, S.; Fusetani, N.; van Soest, R. W. M. Callyspongynic acid, a polyacetylenic acid which inhibits cx glucosidase, from the marine sponge Callyspongia truncata. J. Nat. Prod. 2002, 65, 922-924. [CrossRef] [PubMed]
73. Van Kaer, L. Drugs from the Sea: A marine sponge-derived compound prevents Type 1 diabetes. Sci. World I. 2001, 1, 630-632. [CrossRef] [PubMed]
74. Pascual, I.; Lopez, A.; Cómez, H.; ChappC, M.; Saroyán, A.; Conzález, Y.; Cisneros, M.; Charli, J. L.; Chavez, M. Screening of inhibitors of porcine dipeptidyl peptidase iv activity in aqueous extracts from marine organisms. Enzyme Microb. Technol. 2007, 40, 414-419. [CrossRef]
75. Yamazaki, H.; Sumilat, D. A.; Kanno, S.; Ukai, K.; Rotinsulu, H.; Wewengkang, D. S.; Ishikawa, M.; Mangindaan, R. E.; Namikoshi, M. A polybromodiphenyl ether from an Indonesian marine sponge Lamellodysidea herbacea and its chemical derivatives inhibit protein tyrosine phosphatase 1B, an important target for diabetes treatment. J. Nat. Med. 2013, 67, 730-735. [CrossRef I [PubMed]
76. Zhang, Y.; Li, Y.; Cuo, Y. W.; Jiang, H. L.; Shen, X. A sesquiterpene quinone, dysidine, from the sponge Dysidea villosa, activates the insulin pathway through inhibition of PlPases. Acta Pharm. Sin. 2009, 30, 333-345. [CrossRef] [PubMed]
77. Giannini, C.; Debitus, C.; Lucas, R.; TJbeda, A.; Payá, M.; Hooper, J. N.; D'Auria, M. V. New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte functions. I. Nat. Prod. 2001, 64, 612-615. [CrossRef] [PubMed]
78. Li, Y.; Lhang, Y.; Shen, X.; Guo, Y. W. A novel sesquiterpene quinone from Hainan sponge iJysidea villosa. Bioorg. Med. Chem. Lett. 2009, 19, 390-392. [CrossRef I [PubMed]
79. Zhu, CF.; Li, G.-Z.; Peng, H. B.; Zhang, F.; Chen, Y.; Li, Y. Effect of marine collagen peptides on markers of metabolic nuclear receptors in type 2 diabetic patients with/without hypertension. Biomed. Environ. Sci. 2010, 23, 113-120. [CrossRef]
80. Taouis, M.; Dagou, C.; Ster, C.; Durand, C.; Pinault, M.; Delarue, J. N-3 polyunsaturated fatty acids prevent the defect of insulin receptor signaling in muscle. Am. I. Physiol. Endocrinol. Metab. 2002, 282, E664-E671. [CrossRef] [PubMed]
81. Delarue, J.; Couet, C.; Cohen, R.; Brechot, J. E; Antoine, J. M.; Lamisse, F Effects of fish oil on metabolic responses to oral fructose and glucose loads in healthy humans. Am. I. Physiol. 1996, 270, E353-E362. [PubMed]
82. Lauritano, C.; Procaccini, C.; Janora, A. Gene Expression Patterns and Stress Response in Marine Copepods. Mar. Environ. Res. 2012, 76, 22-31. [CrossRef] [PubMed]
83. Kim, K.; Mendis, E. Bioactive compounds from marine processing byproducts-A review. mt. Food Res. 2006, 39, 383-393. [CrossRef]
84. Harnedy, P. A.; Fitz Gerald, R. J. Bioactive peptides from marine processing waste and shellfish: A review. J. Funct. Foods 2012, 4, 6-24. [CrossRef]
85. Berry, E. M. Dietary fatty acids in the management of diabetes mellitus. Am. J. Clin. Nutr. 1997, 66, 991-997.
86. Sheehan, J. P.; Wei, W.; Ulchaker, M.; Tserng, K. Y Effect of high fiber intake in fish oil-treated patients with non-insulin-dependent diabetes mellitus. Am. J. Clin. Nutr. 1997, 66, 1183-1187. [PubMed]